Primary Progressive MS Research in Phoenix: Understanding the PriMroSe Study

For adults living with primary progressive multiple sclerosis (PPMS), it can be difficult to sort through information about research studies, current care, and the next question to ask. Arizona Neuroscience Research currently lists the PriMroSe study, also called ZB020-03-001, among its enrolling studies in Phoenix. The study is evaluating orelabrutinib in adults with PPMS. Learning about a study is not the same as deciding to join it, and a research listing is not a promise that someone will qualify. Still, knowing what questions to ask can make the process clearer.

This article explains the public information available about PriMroSe, why PPMS research matters, and how an Arizona resident can start a careful conversation with the research team. It is educational only. Your treating clinician remains the right person to discuss your symptoms, diagnosis, and treatment plan.

What is the PriMroSe study?

PriMroSe is the name Arizona Neuroscience Research uses for study ZB020-03-001. The public listing describes it as a global Phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating orelabrutinib in adults with primary progressive multiple sclerosis. The sponsor’s public pipeline describes the study as evaluating orelabrutinib 80 mg once daily compared with placebo, with time to onset of 12-week composite confirmed disability progression as its primary endpoint.

Those research terms are important. A randomized study uses a planned method to assign participants to study groups. “Double-blind” generally means that certain people involved in the study do not know which group a participant is in during the blinded period. A placebo-controlled design compares the investigational medicine with an inactive comparison. The consent form and site staff should explain exactly how these features apply to PriMroSe before anyone agrees to screening or enrollment.

Arizona Neuroscience Research currently lists PriMroSe as enrolling and notes that its public eligibility summary includes adults ages 18 to 60 with PPMS. That summary does not replace the complete study protocol. Local recruitment status, inclusion and exclusion criteria, visit requirements, and final eligibility must all be confirmed directly with the Phoenix research team.

Primary progressive MS in plain language

Multiple sclerosis is a condition in which the immune system is involved in damage to the central nervous system. MS is not the same for every person. PPMS is one form of MS in which neurologic function tends to worsen gradually from the beginning, rather than following the clearer relapses and remissions that some people experience with relapsing forms of MS. The pace and pattern of change can differ greatly between individuals.

People with PPMS may experience changes in walking, balance, strength, sensation, bladder function, fatigue, or other day-to-day activities. These symptoms can also have causes unrelated to MS. A new symptom, a sudden change, or a concern about safety deserves timely medical attention instead of an assumption that it is simply part of the condition.

Research is especially important in progressive forms of MS because it helps investigators study questions that may not be answered by routine care alone. A clinical trial cannot predict what will happen for one person, but it can provide carefully collected information across a group of participants. That evidence can help guide future understanding of possible treatment approaches.

Why a Phase 3 PPMS study may matter

Clinical research moves through different phases, and each phase has a different purpose. A Phase 3 study is typically larger than early-stage research and is designed to evaluate a study treatment under a defined protocol. It may gather information about effectiveness and safety while using planned comparisons and follow-up. That does not mean a treatment is proven or approved for the condition being studied. The purpose of the trial is to answer the research question.

For PriMroSe, the stated primary endpoint relates to 12-week composite confirmed disability progression. That phrase describes a predefined research measurement rather than a personal guarantee. The study staff can explain how the endpoint is evaluated, what assessments may be involved, and what the protocol requires. It is appropriate to ask for plain-language explanations of any outcome measure that feels unclear.

Research participation is voluntary. It is reasonable to read about a study, ask questions, and decide that it is not a fit. It is also reasonable for a person to be interested but not meet the current criteria. Screening is a process, not a promise of enrollment.

What is known publicly about orelabrutinib?

Orelabrutinib is an investigational medicine in the PriMroSe study. The sponsor identifies it as part of its development program for progressive MS. Public descriptions should not be read as a recommendation to take, stop, or change any medicine. Whether research participation is appropriate depends on the protocol, a person’s medical history, current care, and conversations with both the research team and treating clinician.

An investigational medicine is studied because important questions remain. Researchers collect information on potential benefits, risks, side effects, and other outcomes through the planned study. Neither a blog post nor a public study listing can fully explain those details for an individual. The informed-consent discussion is where prospective participants should learn about known and potential risks, alternatives, study procedures, privacy, and the right to withdraw.

What the study does not promise

• It does not promise that someone will be accepted into the study.
• It does not promise access to the investigational medicine.
• It does not promise improved symptoms, slower progression, or a specific result.
• It does not replace a person’s usual medical care or emergency planning.
• It does not mean a participant should make medication changes without medical guidance.

How screening and consent usually work

The first step is often an initial conversation. Arizona Neuroscience Research can confirm whether PriMroSe is currently open in Phoenix and discuss the public criteria at a high level. If someone wants to be considered, the team may ask questions about diagnosis, age, health history, current medicines, prior treatment, and other protocol requirements. They may request records or ask for permission to obtain medical information. The exact process belongs to the current protocol and local research staff.

If screening suggests a potential match, the team should review an informed-consent document. Informed consent is not simply a signature. It is a chance to understand the purpose of the study, what visits and assessments may involve, possible risks and inconveniences, potential alternatives, costs or reimbursements if any, privacy practices, and whom to call with questions. You may take time to read the material, discuss it with people you trust, and ask the study team to explain terms in everyday language.

A person may decide not to participate at any point. A decision about research should be voluntary and should fit the person’s own circumstances. If an answer is not known at the time of your conversation, it is better for the team to check the protocol than for anyone to guess.

Questions to bring to a Phoenix research conversation

Writing down questions can help make an initial call or visit more useful. Consider asking:

• Is PriMroSe, study ZB020-03-001, currently recruiting at Arizona Neuroscience Research?
• What are the current screening steps and the full eligibility criteria?
• How does the study define primary progressive MS for this protocol?
• What visits, tests, questionnaires, or imaging may be required?
• How long might participation last, and how often would visits occur?
• How are study-related questions handled outside a scheduled visit?
• How does study participation relate to my regular neurologic care?
• What are the known and potential risks, alternatives, and privacy protections?

These are questions for learning, not medical advice. The answers can help you decide whether it makes sense to pursue screening.

Keeping research and routine care connected

A clinical trial may involve its own staff, visits, and procedures, while your regular care continues through your usual clinicians. Before screening, ask how those roles are coordinated and what information the study team needs from your treating provider. Bring an updated medication list and a summary of questions or recent changes that matter to you.

Do not delay routine appointments, recommended monitoring, or care for new symptoms because you are waiting to hear about research. A study opportunity can be part of a broader care conversation, but it should not replace it. If a medication or treatment question comes up, discuss it with the clinician managing your care.

When symptoms need urgent help

Research information should never delay emergency care. Call 911 or seek emergency help for sudden facial drooping, trouble speaking, sudden severe weakness, fainting or loss of consciousness, a seizure lasting five minutes or longer, or a sudden severe headache unlike your usual symptoms. For new or worsening neurologic symptoms that are not an emergency, contact your treating clinician promptly for guidance. The research site can explain study procedures, but emergency and urgent clinical needs should be handled through appropriate medical care.

Frequently asked questions about PriMroSe

Is PriMroSe a treatment available through regular care?

No. PriMroSe is a research study. The investigational medicine and study procedures are governed by the study protocol. Ask the research team and your treating clinician how participation relates to your own care.

Is Arizona Neuroscience Research enrolling for PriMroSe?

Arizona Neuroscience Research currently lists PriMroSe as enrolling. Local availability can change, so contact the site directly for the latest status and screening information.

Can everyone with PPMS join?

No. The public listing gives a limited eligibility summary, but the complete protocol has additional criteria. The study team makes eligibility decisions after screening.

Will a participant receive orelabrutinib?

PriMroSe is described as randomized and placebo-controlled. The consent process should explain study groups, the chance of receiving each study intervention, and other protocol details. No outcome or treatment assignment can be promised in advance.

Where can I learn more in Arizona?

Review Arizona Neuroscience Research’s Current Studies page and submit an inquiry through Volunteer Today. The public study record is also available at ClinicalTrials.gov.

Next steps for Arizona residents interested in PPMS research

If you live in Phoenix or elsewhere in Arizona and are interested in PPMS research, start with a simple, informed conversation. Review the current PriMroSe listing, speak with the Arizona Neuroscience Research team about local availability, and bring your questions. You do not need to decide during the first contact. A good research discussion gives you the information needed to decide whether screening is worth considering.

Arizona Neuroscience Research lists locations near Bell Road and in the Biltmore area. Use the current website for contact details and availability because local study information can change. Research participation is voluntary, and the study team can explain the current protocol, possible next steps, and whether screening may be appropriate.

This article is for education and does not provide medical advice, diagnosis, or treatment. Research participation is voluntary. Eligibility, availability, procedures, risks, and potential benefits must be reviewed with the research team and the participant’s treating clinician.

Before you contact a study site, consider noting your diagnosis history, questions about travel and appointment timing, and the people you would like involved in your decision. Clear information supports a voluntary, unhurried choice.